Shuhua Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shuhua Chen has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Hong Xiang
Center for Experimental Medical Research, the Third Xiangya Hospital of Central South University, Changsha, China
4 shared publications- Hongwei Lu
Center for Experimental Medicine, The Third Xiangya Hospital of Central South University, Changsha, China
4 shared publications Hang Zou
Department of Biochemistry and Molecular Biology, School of Life Sciences, Central South University, Changsha, China
2 shared publicationsXuewen Wang
Department of Cardiology, Third Xiangya Hospital of Central South University, Changsha, China
2 shared publicationsYing Chen
Department of Biochemistry and Molecular Biology, School of Life Sciences, Central South University, Changsha, China
2 shared publicationsZhihao Shu
Center for Experimental Medical Research, the Third Xiangya Hospital of Central South University, Changsha, China
2 shared publications
Latest Publications
- 12 February 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 247, 117794
PACS2 deficiency ameliorates hepatic steatosis via inhibition of the JNK signaling pathway in diabetic mice
- 12 February 2026
- Published by Elsevier in Biochemical Pharmacology
- Vol. 247, 117794
PACS2 deficiency ameliorates hepatic steatosis via inhibition of the JNK signaling pathway in diabetic mice
- 1 January 2026
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 54 (02) , 603-625
Quercetin Alleviates Endothelial Dysfunction in Atherosclerosis by Inhibiting Ferroptosis Through PACS2/HMOX-1 Pathway
Atherosclerosis is a leading cause of worldwide cardiovascular morbidity and mortality, and endothelial ferroptosis has emerged as a key mechanism in driving vascular injury. This study aimed to investigate whether quercetin (QCT), a natural dietary flavonoid with potent anti-oxidant activity, protects against atherosclerosis-associated endothelial dysfunction by modulating ferroptosis. In order to test this, ApoE[ ] mice fed a high-fat diet were treated with QCT or ferrostatin-1, and their aortic plaque burden, stability, and macrophage infiltration were then assessed. To evaluate ferroptosis, human umbilical vein endothelial cells (HUVECs) were exposed to oxidized low-density lipoprotein (Ox-LDL), with or without QCT, and their reactive oxygen species (ROS), Fe[ ] accumulation, and heme oxygenase-1 (HMOX-1) expression were measured. While functional assays examined endothelial barrier integrity and monocyte adhesion, gene modulation studies explored the role of phosphofurin acidic cluster sorting protein 2 (PACS2). QCT treatment markedly reduced plaque area, necrotic core size, and macrophage infiltration while enhancing plaque stability. In vitro, QCT suppressed Ox-LDL-induced ferroptosis by decreasing ROS and Fe[ ] levels and downregulating HMOX-1 to thereby restore endothelial integrity and reduce monocyte adhesion. Mechanistically, QCT restored PACS2 expression suppressed by Ox-LDL. However, PACS2 knockdown or HMOX-1 activation abrogated QCT’s protective effects. These findings identify QCT as a promising dietary anti-oxidant that mitigates atherosclerosis via the PACS2-HMOX-1 ferroptosis pathway.
- 1 January 2026
- Published by World Scientific Pub Co Pte Ltd in The American Journal of Chinese Medicine
- Vol. 54 (02) , 603-625
Quercetin Alleviates Endothelial Dysfunction in Atherosclerosis by Inhibiting Ferroptosis Through PACS2/HMOX-1 Pathway
Atherosclerosis is a leading cause of worldwide cardiovascular morbidity and mortality, and endothelial ferroptosis has emerged as a key mechanism in driving vascular injury. This study aimed to investigate whether quercetin (QCT), a natural dietary flavonoid with potent anti-oxidant activity, protects against atherosclerosis-associated endothelial dysfunction by modulating ferroptosis. In order to test this, ApoE[ ] mice fed a high-fat diet were treated with QCT or ferrostatin-1, and their aortic plaque burden, stability, and macrophage infiltration were then assessed. To evaluate ferroptosis, human umbilical vein endothelial cells (HUVECs) were exposed to oxidized low-density lipoprotein (Ox-LDL), with or without QCT, and their reactive oxygen species (ROS), Fe[ ] accumulation, and heme oxygenase-1 (HMOX-1) expression were measured. While functional assays examined endothelial barrier integrity and monocyte adhesion, gene modulation studies explored the role of phosphofurin acidic cluster sorting protein 2 (PACS2). QCT treatment markedly reduced plaque area, necrotic core size, and macrophage infiltration while enhancing plaque stability. In vitro, QCT suppressed Ox-LDL-induced ferroptosis by decreasing ROS and Fe[ ] levels and downregulating HMOX-1 to thereby restore endothelial integrity and reduce monocyte adhesion. Mechanistically, QCT restored PACS2 expression suppressed by Ox-LDL. However, PACS2 knockdown or HMOX-1 activation abrogated QCT’s protective effects. These findings identify QCT as a promising dietary anti-oxidant that mitigates atherosclerosis via the PACS2-HMOX-1 ferroptosis pathway.
- Open Access
- 13 May 2022
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (12) , 3313-3322
Research progress of endothelial‐mesenchymal transition in diabetic kidney disease
Renal fibrosis is an important pathological feature of diabetic kidney disease (DKD), manifested as tubular interstitial fibrosis, tubular atrophy, glomerulosclerosis and damage to the normal structure of the kidney. Renal fibrosis can eventually develop into renal failure. A better understanding of renal fibrosis in DKD is needed due to clinical limitations of current anti‐fibrotic drugs in terms of effectiveness, cost‐effectiveness and side effects. Fibrosis is characterized by local excessive deposition of extracellular matrix, which is derived from activated myofibroblasts to increase its production or specific tissue inhibitors of metalloproteinases to reduce its degradation. In recent years, endothelial‐mesenchymal transition (EndMT) has gradually integrated into the pathogenesis of fibrosis. In animal models of diabetic kidney disease, it has been found that EndMT is involved in the formation of renal fibrosis and multiple signalling pathways such as TGF‐β signalling pathway, Wnt signalling pathway and non‐coding RNA network participate in the regulation of EndMT during fibrosis. Here, we mainly review EndMT regulation and targeted therapy of renal fibrosis in DKD.
- 13 May 2022
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 26 (12) , 3313-3322
Open AccessResearch progress of endothelial‐mesenchymal transition in diabetic kidney disease
Renal fibrosis is an important pathological feature of diabetic kidney disease (DKD), manifested as tubular interstitial fibrosis, tubular atrophy, glomerulosclerosis and damage to the normal structure of the kidney. Renal fibrosis can eventually develop into renal failure. A better understanding of renal fibrosis in DKD is needed due to clinical limitations of current anti‐fibrotic drugs in terms of effectiveness, cost‐effectiveness and side effects. Fibrosis is characterized by local excessive deposition of extracellular matrix, which is derived from activated myofibroblasts to increase its production or specific tissue inhibitors of metalloproteinases to reduce its degradation. In recent years, endothelial‐mesenchymal transition (EndMT) has gradually integrated into the pathogenesis of fibrosis. In animal models of diabetic kidney disease, it has been found that EndMT is involved in the formation of renal fibrosis and multiple signalling pathways such as TGF‐β signalling pathway, Wnt signalling pathway and non‐coding RNA network participate in the regulation of EndMT during fibrosis. Here, we mainly review EndMT regulation and targeted therapy of renal fibrosis in DKD.
- Open Access
- 12 May 2022
- Published by SAGE Publications in Diabetes & Vascular Disease Research
- Vol. 19 (3)
Glucolipotoxicity induces endothelial cell dysfunction by activating autophagy and inhibiting autophagic flow
Objectives: This study aims to determine the role and mechanism of autophagy in endothelial cell dysfunction by glucolipotoxicity. Methods: Human umbilical vein endothelial cells (HUVECs) were treated with high glucose and high palmitic acid. The number of autophagosomes was evaluated by monodansylcadaverine (MDC) staining and transmission electron microscopy (TEM). The expression of autophagy-related proteins (LC3 and P62) was assessed by Western blotting. Capillary tube-like formation was evaluated on Matrigel. Reactive oxygen species (ROS) production was detected by DCFH-DA. Cell apoptosis was measured by Hoechst 33258 staining and flow cytometry. Phosphorylation of AMPK, mTOR, and ULK1 was also analyzed by Western blotting. Results: We found that glucolipotoxicity induced autophagy initiation and hindered autophagosomes degradation. Moreover, glucolipotoxicity increased the production of intracellular ROS, decreased the ability of tubular formation, and increased cell apoptosis. However, endothelial cell dysfunction was alleviated by 3-methyladenine, an early-stage autophagy inhibitor. Additionally, glucolipotoxicity promoted the phosphorylation of AMPK and ULK1 and inhibited the phosphorylation of mTOR. Conclusions: Glucolipotoxicity initiates autophagy through the AMPK/mTOR/ULK1 signaling pathway and inhibits autophagic flow, leading to the accumulation of autophagosomes, thereby inducing apoptosis and impairing endothelial cell function.
- 12 May 2022
- Published by SAGE Publications in Diabetes & Vascular Disease Research
- Vol. 19 (3)
Open AccessGlucolipotoxicity induces endothelial cell dysfunction by activating autophagy and inhibiting autophagic flow
Objectives: This study aims to determine the role and mechanism of autophagy in endothelial cell dysfunction by glucolipotoxicity. Methods: Human umbilical vein endothelial cells (HUVECs) were treated with high glucose and high palmitic acid. The number of autophagosomes was evaluated by monodansylcadaverine (MDC) staining and transmission electron microscopy (TEM). The expression of autophagy-related proteins (LC3 and P62) was assessed by Western blotting. Capillary tube-like formation was evaluated on Matrigel. Reactive oxygen species (ROS) production was detected by DCFH-DA. Cell apoptosis was measured by Hoechst 33258 staining and flow cytometry. Phosphorylation of AMPK, mTOR, and ULK1 was also analyzed by Western blotting. Results: We found that glucolipotoxicity induced autophagy initiation and hindered autophagosomes degradation. Moreover, glucolipotoxicity increased the production of intracellular ROS, decreased the ability of tubular formation, and increased cell apoptosis. However, endothelial cell dysfunction was alleviated by 3-methyladenine, an early-stage autophagy inhibitor. Additionally, glucolipotoxicity promoted the phosphorylation of AMPK and ULK1 and inhibited the phosphorylation of mTOR. Conclusions: Glucolipotoxicity initiates autophagy through the AMPK/mTOR/ULK1 signaling pathway and inhibits autophagic flow, leading to the accumulation of autophagosomes, thereby inducing apoptosis and impairing endothelial cell function.
- Open Access
- 15 December 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 810224
LKB1 Regulates Vascular Macrophage Functions in Atherosclerosis
Liver kinase B1 (LKB1) is known to shape the regulation of macrophage function by participating in multiple processes including cell metabolism, growth, and polarization. However, whether LKB1 also affects the functional plasticity of macrophages in atherosclerosis has not attracted much attention. Abnormal macrophage function is a pathophysiological hallmark of atherosclerosis, characterized by the formation of foam cells and the maintenance of vascular inflammation. Mounting evidence supports that LKB1 plays a vital role in the regulation of macrophage function in atherosclerosis, including affecting lipid metabolism reprogramming, inflammation, endoplasmic reticulum stress, and autophagy in macrophages. Thus, decreased expression of LKB1 in atherosclerosis aggravates vascular injury by inducing excessive lipid deposition in macrophages and the formation of foam cells. To systematically understand the role and potential mechanism of LKB1 in regulating macrophage functions in atherosclerosis, this review summarizes the relevant data in this regard, hoping to provide new ideas for the prevention and treatment of atherosclerosis.
- 15 December 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12, 810224
Open AccessLKB1 Regulates Vascular Macrophage Functions in Atherosclerosis
Liver kinase B1 (LKB1) is known to shape the regulation of macrophage function by participating in multiple processes including cell metabolism, growth, and polarization. However, whether LKB1 also affects the functional plasticity of macrophages in atherosclerosis has not attracted much attention. Abnormal macrophage function is a pathophysiological hallmark of atherosclerosis, characterized by the formation of foam cells and the maintenance of vascular inflammation. Mounting evidence supports that LKB1 plays a vital role in the regulation of macrophage function in atherosclerosis, including affecting lipid metabolism reprogramming, inflammation, endoplasmic reticulum stress, and autophagy in macrophages. Thus, decreased expression of LKB1 in atherosclerosis aggravates vascular injury by inducing excessive lipid deposition in macrophages and the formation of foam cells. To systematically understand the role and potential mechanism of LKB1 in regulating macrophage functions in atherosclerosis, this review summarizes the relevant data in this regard, hoping to provide new ideas for the prevention and treatment of atherosclerosis.